Literature DB >> 22955358

Mucosal permeability and immune activation as potential therapeutic targets of probiotics in irritable bowel syndrome.

Giovanni Barbara1, Lisa Zecchi, Raffaella Barbaro, Cesare Cremon, Lara Bellacosa, Marco Marcellini, Roberto De Giorgio, Roberto Corinaldesi, Vincenzo Stanghellini.   

Abstract

There is increasingly convincing evidence supporting the participation of the gut microenvironment in the pathophysiology of irritable bowel syndrome (IBS). Studies particularly suggest an interplay between luminal factors (eg, foods and bacteria residing in the intestine), the epithelial barrier, and the mucosal immune system. Decreased expression and structural rearrangement of tight junction proteins in the small bowel and colon leading to increased intestinal permeability have been observed, particularly in postinfectious IBS and in IBS with diarrhea. These abnormalities are thought to contribute to the outflow of antigens through the leaky epithelium, causing overstimulation of the mucosal immune system. Accordingly, subsets of patients with IBS show higher numbers and an increased activation of mucosal immunocytes, particularly mast cells. Immune factors, released by these cells, including proteases, histamine, and prostanoids, participate in the perpetuation of the permeability dysfunction and contribute to the activation of abnormal neural responses involved in abdominal pain perception and changes in bowel habits. All these mechanisms represent new targets for therapeutic approaches in IBS. Probiotics are an attractive therapeutic option in IBS given their recognized safety and by virtue of positive biological effects they can exert on the host. Of importance for the IBS pathophysiology is that preclinical studies have shown that selective probiotic strains exhibit potentially useful properties including anti-inflammatory effects, improvement of mucosal barrier homeostasis, beneficial effects on intestinal microbiota, and a reduction of visceral hypersensitivity. The effect of probiotics on IBS is positive in most randomized, controlled studies, although the gain over the placebo is small. Identifying tailored probiotic approaches for subgroups of IBS patients represents a challenge for the future.

Entities:  

Mesh:

Year:  2012        PMID: 22955358     DOI: 10.1097/MCG.0b013e318264e918

Source DB:  PubMed          Journal:  J Clin Gastroenterol        ISSN: 0192-0790            Impact factor:   3.062


  33 in total

1.  The gut microbiota keeps enteric glial cells on the move; prospective roles of the gut epithelium and immune system.

Authors:  Panagiotis S Kabouridis; Reena Lasrado; Sarah McCallum; Song Hui Chng; Hugo J Snippert; Hans Clevers; Sven Pettersson; Vassilis Pachnis
Journal:  Gut Microbes       Date:  2015

Review 2.  New therapeutic perspectives in irritable bowel syndrome: Targeting low-grade inflammation, immuno-neuroendocrine axis, motility, secretion and beyond.

Authors:  Emanuele Sinagra; Gaetano Cristian Morreale; Ghazaleh Mohammadian; Giorgio Fusco; Valentina Guarnotta; Giovanni Tomasello; Francesco Cappello; Francesca Rossi; Georgios Amvrosiadis; Dario Raimondo
Journal:  World J Gastroenterol       Date:  2017-09-28       Impact factor: 5.742

Review 3.  Chemical and molecular factors in irritable bowel syndrome: current knowledge, challenges, and unanswered questions.

Authors:  Michael Camilleri; Ibironke Oduyebo; Houssam Halawi
Journal:  Am J Physiol Gastrointest Liver Physiol       Date:  2016-09-08       Impact factor: 4.052

Review 4.  Irritable bowel syndrome: a clinical review.

Authors:  Rosa L S Soares
Journal:  World J Gastroenterol       Date:  2014-09-14       Impact factor: 5.742

Review 5.  Corticotropin-releasing factor receptor type 1 and type 2 interaction in irritable bowel syndrome.

Authors:  Tsukasa Nozu; Toshikatsu Okumura
Journal:  J Gastroenterol       Date:  2015-05-12       Impact factor: 7.527

Review 6.  Chronic functional bowel syndrome enhances gut-brain axis dysfunction, neuroinflammation, cognitive impairment, and vulnerability to dementia.

Authors:  Mak Adam Daulatzai
Journal:  Neurochem Res       Date:  2014-03-04       Impact factor: 3.996

Review 7.  Stress and the Microbiota-Gut-Brain Axis in Visceral Pain: Relevance to Irritable Bowel Syndrome.

Authors:  Rachel D Moloney; Anthony C Johnson; Siobhain M O'Mahony; Timothy G Dinan; Beverley Greenwood-Van Meerveld; John F Cryan
Journal:  CNS Neurosci Ther       Date:  2015-12-10       Impact factor: 5.243

Review 8.  Indication of immune activation in patients with perceived food hypersensitivity.

Authors:  Gülen Arslan Lied
Journal:  Dig Dis Sci       Date:  2013-11-02       Impact factor: 3.199

9.  Lipopolysaccharide induces visceral hypersensitivity: role of interleukin-1, interleukin-6, and peripheral corticotropin-releasing factor in rats.

Authors:  Tsukasa Nozu; Saori Miyagishi; Rintaro Nozu; Kaoru Takakusaki; Toshikatsu Okumura
Journal:  J Gastroenterol       Date:  2016-04-13       Impact factor: 7.527

10.  Lactobacillus acidophilus Induces a Strain-specific and Toll-Like Receptor 2-Dependent Enhancement of Intestinal Epithelial Tight Junction Barrier and Protection Against Intestinal Inflammation.

Authors:  Rana Al-Sadi; Prashant Nighot; Meghali Nighot; Mohammad Haque; Manmeet Rawat; Thomas Y Ma
Journal:  Am J Pathol       Date:  2021-02-16       Impact factor: 4.307

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.